Absolutely. Adam is NOT to be trusted. Anyone who thinks otherwise has not been paying attention to biotech for the last decade. He used to be identified in thestreet's 10-k as "a short advisor"--maybe still is.
Fartstain is a manipulator, or more correctly--the tool of a manipulator. He used to be identified in thestreet's 10K as "a short advisor." Methinks he still is. JMHO, of course.
Big news. There will be more articles. Four million shares in first 15 minutes. Impressive volume.
"Typically, myelofibrosis is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow,” Dr. Tefferi says. “Some patients in our trial have reverted back to normal bone marrow.”
Very exciting news!!!!!!
It's a title that gets one's attention--isn't it?
MPACs compete with Aβ for binding with redox-active metal ions, subsequently preventing Aβ oligomerization.
What Prana has so far.
They have shown PBT1 demonstrating a weak but increasing efficacy out to 84 weeks in very advanced Alzheimers patients.
They have the more potent analog of PBT1, PBT2 demonstrating an 82% response and reversing alzheimers brain damage in just 12 weeks in a human clinical trial.
* in a mouse model that the APP protein is involved in the iron removal process and that the build up of metals outside he synapse prevents the APP performing that function.
* PBT2 can remove the metals from the plaques around the synapses and neurons, breaking up the plaques in the process,at the same time restoring the iron removal function of the APP.
* neuron and dendrite(neuron connections) repair with PBT2 in the prsence of copper/zinc.
* Harvard has revealed that the amyloid works as a antimicrobial peptide and total removal of amyloid is perhaps not a good thing.
*that PBT2 releases the metals removed from the plaques back into the neurons where they are essential for normal function.
* one of the functions of zinc repositioning back into the neurons, is down regulation of GSK3, which down regulates Tau. One of the accepted causes of Alzheimers.
* PBT2 can inhibit excitotoxicity, the cause of neuron cell death in diseases from Huntingtons to HIV.
* in a mouse model normal age related memory loss eliminated. Cognition was restored to the same level as young animals.
* now these research results from an independent company reveal PBT2 can stop the plaques aggregating and prevent toxic oligomers causing damage at he synapse.
Most of the above has already been published
They also have some exciting pre clinical results on Parkinsons, Huntingtons and brain cancer.
PIVALDE in response to Whale 11/26/11
I think Tanzi could have said tha
"Anything for an edge. Anything to make a flat pond a little less flat."
Precisely. This could be the hedge fund credo.
Large clinics will be the fastest growers of revenue because they are the fastest early-adopters. I also agree that they will be the ones with the automated systems on site.
Seems like the FDA's new "breakthrough therapy" designation should apply to imetelstat:
"In July 2012, a provision in the new law gave FDA another powerful expedited development tool, known as the “breakthrough therapy” designation. This new designation is now helping FDA assist drug developers expedite the development of new drugs with preliminary clinical evidence that indicates the drug may offer a substantial improvement over available therapies for patients with serious or life-threatening diseases."
I think the results of the current Mayo Clinic trial will get people thinking about broader application in their own special fields of clinical research.
Yes, the Breakthrough Therapy designation seems to apply to Geron. The FDA has recently adjusted their thinking a bit when it comes to unmet needs of patients, due in part to a lot of pressure from patient advocacy groups. Many voices can make a difference.